Vitrolife AB (publ)

LSE:0YAY Stock Report

Market Cap: SEK 21.4b

Vitrolife Valuation

Is 0YAY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0YAY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 230.58
Fair Value
31.3% undervalued intrinsic discount
5
Number of Analysts

Below Fair Value: 0YAY (SEK158.46) is trading below our estimate of fair value (SEK230.58)

Significantly Below Fair Value: 0YAY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0YAY?

Key metric: As 0YAY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0YAY. This is calculated by dividing 0YAY's market cap by their current earnings.
What is 0YAY's PE Ratio?
PE Ratio43x
EarningsSEK 498.00m
Market CapSEK 21.42b

Price to Earnings Ratio vs Peers

How does 0YAY's PE Ratio compare to its peers?

The above table shows the PE ratio for 0YAY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.9x
BVXP Bioventix
19xn/aUK£148.9m
PRTC PureTech Health
7.5x-90.44%UK£300.7m
HCM HUTCHMED (China)
68.8x15.99%UK£1.9b
HIK Hikma Pharmaceuticals
16.4x11.60%UK£4.4b
0YAY Vitrolife
43x18.59%SEK 21.4b

Price-To-Earnings vs Peers: 0YAY is expensive based on its Price-To-Earnings Ratio (43x) compared to the peer average (27.9x).

Price to Earnings Ratio vs Industry

How does 0YAY's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0YAY 43.0xIndustry Avg. 26.7xNo. of Companies6PE020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0YAY is expensive based on its Price-To-Earnings Ratio (43x) compared to the European Biotechs industry average (26.7x).

Price to Earnings Ratio vs Fair Ratio

What is 0YAY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0YAY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio43x
Fair PE Ratio29x

Price-To-Earnings vs Fair Ratio: 0YAY is expensive based on its Price-To-Earnings Ratio (43x) compared to the estimated Fair Price-To-Earnings Ratio (29x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0YAY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 158.46
SEK 242.40
+52.97%
6.82%SEK 265.00SEK 227.00n/a5
May ’26SEK 155.88
SEK 243.40
+56.15%
7.26%SEK 265.00SEK 227.00n/a5
Apr ’26SEK 163.10
SEK 256.60
+57.33%
5.46%SEK 268.00SEK 230.00n/a5
Mar ’26SEK 188.97
SEK 269.20
+42.46%
2.43%SEK 278.00SEK 260.00n/a5
Feb ’26SEK 222.00
SEK 270.20
+21.71%
2.83%SEK 280.00SEK 260.00n/a5
Jan ’26SEK 215.00
SEK 273.33
+27.13%
3.45%SEK 280.00SEK 260.00n/a3
Dec ’25SEK 225.74
SEK 273.33
+21.08%
3.45%SEK 280.00SEK 260.00n/a3
Nov ’25SEK 234.60
SEK 271.67
+15.80%
3.13%SEK 280.00SEK 260.00n/a3
Oct ’25SEK 253.65
SEK 271.67
+7.10%
3.13%SEK 280.00SEK 260.00n/a3
Sep ’25SEK 246.76
SEK 261.67
+6.04%
3.93%SEK 275.00SEK 250.00n/a3
Aug ’25SEK 231.71
SEK 261.67
+12.93%
3.93%SEK 275.00SEK 250.00n/a3
Jul ’25SEK 173.50
SEK 231.67
+33.53%
10.33%SEK 265.00SEK 210.00n/a3
Jun ’25SEK 182.60
SEK 231.67
+26.87%
10.33%SEK 265.00SEK 210.00n/a3
May ’25SEK 166.30
SEK 231.67
+39.31%
10.33%SEK 265.00SEK 210.00SEK 155.883
Apr ’25SEK 200.70
SEK 248.33
+23.73%
6.64%SEK 270.00SEK 230.00SEK 163.103
Mar ’25SEK 180.00
SEK 248.33
+37.96%
6.64%SEK 270.00SEK 230.00SEK 188.973
Feb ’25SEK 169.35
SEK 241.67
+42.71%
8.67%SEK 270.00SEK 220.00SEK 222.003
Jan ’25SEK 194.80
SEK 255.00
+30.90%
7.34%SEK 280.00SEK 235.00SEK 215.003
Dec ’24SEK 181.39
SEK 250.00
+37.83%
9.80%SEK 280.00SEK 220.00SEK 225.743
Nov ’24SEK 143.08
SEK 256.67
+79.38%
12.86%SEK 300.00SEK 220.00SEK 234.603
Oct ’24SEK 149.05
SEK 281.67
+88.98%
5.09%SEK 300.00SEK 265.00SEK 253.653
Sep ’24SEK 150.32
SEK 281.67
+87.37%
5.09%SEK 300.00SEK 265.00SEK 246.763
Aug ’24SEK 162.33
SEK 281.67
+73.52%
5.09%SEK 300.00SEK 265.00SEK 231.713
Jul ’24SEK 209.75
SEK 315.00
+50.18%
4.67%SEK 330.00SEK 295.00SEK 173.503
Jun ’24SEK 220.12
SEK 321.67
+46.13%
6.00%SEK 340.00SEK 295.00SEK 182.603
May ’24SEK 231.01
SEK 321.67
+39.24%
6.00%SEK 340.00SEK 295.00SEK 166.303
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
SEK 242.80
Fair Value
34.7% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 00:57
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vitrolife AB (publ) is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
null nullABG Sundal Collier Sponsored
Kallum TitchmarshBofA Global Research